title: Polymorphisms in the MDM2 gene and risk of malignant bone tumors: a meta-analysis.
abstract: There are several studies published to assess the associations of murine double minute 2 (MDM2) genetic polymorphisms with risk of malignant bone tumors, but they reported contradictory results and failed to confirm a strong and consistent association. To assess the evidence regarding the associations of MDM2 genetic polymorphisms with the risk of malignant bone tumors, we conducted a meta-analysis of epidemiological studies. The pooled odds ratio (OR) with its 95% confidence intervals (95% CI) was used to assess these possible associations. Four studies with a total of 3,958 individuals were finally included the meta-analysis. Meta-analysis of two studies on MDM2 SNP309 polymorphism showed that MDM2 SNP309 polymorphism was associated with an increased risk of malignant bone tumors (G versus T: OR = 1.72, 95% CI 1.35-2.20, P < 0.001; GG versus TT: OR = 2.64, 95% CI 1.59-4.39, P < 0.001; GG/GT versus TT: OR = 1.87, 95% CI 1.33-2.62, P < 0.001; GG versus TT/GT: OR = 2.20, 95% CI 1.38-3.51, P = 0.001). Meta-analysis of those two studies on MDM2 rs1690916 polymorphism showed that MDM2 rs1690916 minor allele A was associated with decreased risk of malignant bone tumors (OR = 0.60, 95% CI 0.46-0.77, P < 0.001). Meta-analyses of available data show that there are significant associations of MDM2 SNP309 polymorphism and MDM2 rs1690916 polymorphism with malignant bone tumors.
authors: Department of Orthopedic Surgery, Shanghai Sixth People's Hospital, Shanghai Jiaotong University, 600 Yishan Road, Shanghai, 200233, China.
authors: Jianfei
authors: J
authors: Tang
authors: Longxiang
authors: L
authors: Shen
authors: Sa
authors: S
authors: Song
authors: Zhiquan
authors: Z
authors: An
authors: Changqing
authors: C
authors: Zhang
mesh_terms: D000483:Alleles; D001859:Bone Neoplasms / Q000235:genetics*; D016022:Case-Control Studies; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D006801:Humans; D016017:Odds Ratio; D011110:Polymorphism, Genetic; D020641:Polymorphism, Single Nucleotide; D051736:Proto-Oncogene Proteins c-mdm2 / Q000235:genetics*; D012306:Risk
chemical_list: D051736:Proto-Oncogene Proteins c-mdm2
references: Transcription. 2011 Sep-Oct;2(5):207-10
references: 22231115
references: Mol Biol Rep. 2012 Sep;39(9):9265-74
references: 22729912
references: Nat Rev Mol Cell Biol. 2011 Jun 23;12(7):439-52
references: 21697901
references: Leuk Lymphoma. 2012 Nov;53(11):2245-52
references: 22563815
references: Bull Exp Biol Med. 2012 Oct;153(6):869-73
references: 23113306
references: Oncogene. 2007 Feb 26;26(9):1317-23
references: 17322917
references: Oncogene. 2010 Jul 29;29(30):4253-60
references: 20498634
references: Pediatr Blood Cancer. 2009 Dec;53(6):941-52
references: 19618453
references: Nat Rev Clin Oncol. 2011 Jan;8(1):25-37
references: 20975744
references: BMC Cancer. 2011 May 29;11:209
references: 21619704
references: Radiol Clin North Am. 2011 Nov;49(6):1135-61, v
references: 22024292
references: Clin Cancer Res. 2013 Jan 1;19(1):34-41
references: 23262034
references: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references: 13655060
references: Control Clin Trials. 1986 Sep;7(3):177-88
references: 3802833
references: Semin Diagn Pathol. 2011 Feb;28(1):86-101
references: 21675380
references: Curr Med Chem. 2010;17(28):3142-54
references: 20666726
references: Clin Cancer Res. 2011 Feb 1;17(3):416-26
references: 21159888
references: Mayo Clin Proc. 2012 May;87(5):475-87
references: 22560526
references: Clin Cancer Res. 2009 May 15;15(10):3550-6
references: 19451596
references: JAMA. 2000 Apr 19;283(15):2008-12
references: 10789670
references: PLoS One. 2012;7(7):e41546
references: 22844496
references: PLoS One. 2013;8(2):e56918
references: 23451111
references: Pharmacol Ther. 2012 Jun;134(3):338-44
references: 22401778
references: Hum Cell. 2011 Jun;24(2):57-64
references: 21547352
references: BMJ. 2003 Sep 6;327(7414):557-60
references: 12958120